antibody

Rabbit anti Apo AI, Mouse

MBS315477

0.5 mg

685 USD

polyclonal

rabbit

nonconjugated

human, mouse

western blot, ELISA, enzyme immunoassay

Antibody

Rabbit anti Apo AI, Mouse

Apolipoprotein AI (Apo AI)

Rabbit Antibody to Mouse Apolipoprotein AI (Apo AI)

apolipoprotein AI; Apolipoprotein A-I; apolipoprotein A-I; apo-AI; apoA-I; OTTHUMP00000043268; OTTHUMP00000069346; OTTHUMP00000069347; OTTHUMP00000069348; apolipoprotein A-I; Apolipoprotein A1

APOA1; APOA1; MGC117399

APOA1_HUMAN

Polyclonal

Rabbit

Mouse

267

Apolipoprotein AI (Apo AI). Recognizes mouse and rat Apo AI. Does not react well with human Apo AI.

Immunoaffinity chromatography

Affinity Purified, Liquid

1mg/ml

Store (up to 1 year) at 2 to 8 degree C. DO NOT FREEZE.

EIA/ELISA, RID, Western Blot

Immunogen: Purified mouse apolipoprotein AI from pooled mouse plasma high density lipoprotein. (Catalog #MBS318029)

Buffer: 10mM Tris, 0.15M Sodium chloride, pH 8.0. Preservative: 0.02% Sodium azide. Important Note: Centrifuge before opening to ensure complete recovery of vial contents. Warnings: This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1-1.0%. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.

Polyclonal Antibodies to Lipoproteins

Brown, R.J., et al., (2004), "Severe Hypoalphalipoproteinemia in Mice Expressing Human Hepatic Lipase Deficient in Binding to Heparan Sulfate Proteoglycan", The Journal of Biological Chemistry, 279(41): 42403-42409. Conde-Knape,

296635

CAA25519.1

P02647

30,778 Da

ABC-family Proteins Mediated Transport Pathway 106573!!African Trypanosomiasis Pathway 194384!!African Trypanosomiasis Pathway 194323!!Amyloids Pathway 366238!!Chylomicron-mediated Lipid Transport Pathway 106157!!FOXA2 And FOXA3 Transcription Factor Networks Pathway 137911!!Fat Digestion And Absorption Pathway 194385!!Fat Digestion And Absorption Pathway 194324!!Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway 160977!!Folate Metabolism Pathway 198833

This gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. [provided by RefSeq]

Function: Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. Ref.20. Subunit structure: Interacts with APOA1BP and CLU. Component of a sperm activating protein complex (SPAP), consisting of APOA1, an immunoglobulin heavy chain, an immunoglobulin light chain and albumin. Ref.25 Ref.31. Subcellular location: Secreted. Tissue specificity: Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. Ref.33. Post-translational modification: Palmitoylated. Ref.28Phosphorylation sites are present in the extracelllular medium. Involvement in disease: Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [. MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant. Ref.37 Ref.38Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [. MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I. Ref.37 Ref.38Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [. MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed. Ref.37 Ref.38 Ref.43 Ref.44Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [. MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. Ref.37 Ref.38 Ref.46. Sequence similarities: Belongs to the apolipoprotein A1/A4/E family.

0.5 mg

685 USD